NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Get Started

$67.38 -0.15 (-0.22 %)

(As of 05/28/2018 01:15 AM ET)

Previous Close$67.38

Today's Range$67.00 - $67.93

52-Week Range$63.76 - $89.54

Volume4.86 million shs

Average Volume8.55 million shs

Market Capitalization$87.61 billion

P/E Ratio7.87

Dividend Yield3.38%

Beta1.19

About Gilead Sciences (NASDAQ:GILD)

Warning: file_get_contents(): SSL: Handshake timed out in /home/ledgergazette/public_html/download.php on line 7 Warning: file_get_contents(): Failed to enable crypto in /home/ledgergazette/public_html/download.php on line 7 Warning: file_get_contents(https://ca.finance.yahoo.com/quote/GILD/profile?p=GILD): failed to open stream: operation failed in /home/ledgergazette/public_html/download.php on line 7

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:GILD

CUSIP37555810

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.32

Current Ratio2.84

Quick Ratio2.75

Price-To-Earnings

Trailing P/E Ratio7.87

Forward P/E Ratio11.72

P/E Growth-5.86

Sales & Book Value

Annual Sales$26.11 billion

Price / Sales3.36

Cash Flow$9.6257 per share

Price / Cash7.00

Book Value$15.88 per share

Price / Book4.24

Profitability

EPS (Most Recent Fiscal Year)$8.56

Net Income$4.63 billion

Net Margins14.03%

Return on Equity45.49%

Return on Assets15.63%

Miscellaneous

Employees10,000

Outstanding Shares1,300,260,000

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, May 1st. Stockholders of record on Friday, June 15th will be given a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend is Thursday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.19. The biopharmaceutical company earned $5.09 billion during the quarter, compared to analysts' expectations of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. Gilead Sciences's quarterly revenue was down 21.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.23 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

23 equities research analysts have issued 1 year price targets for Gilead Sciences' shares. Their predictions range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.1458 in the next year. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead’s first-quarter results were disappointing with both earnings and sales missing estimates as the magnitude of the decline in HCV sales was wider-than-expected due to lower patient starts and increasing competition. Nevertheless, Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. The CHMP has also adopted a positive opinion on the regimen and a tentative approval is expected in the third-quarter. The initial uptake of Yescarta is encouraging. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio.Shares have performed better than the industry in the last twelve months." (5/7/2018)
2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
5. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), Crispr Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO) and Atara Biotherapeutics (ATRA).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

Dr. John F. Milligan, CEO, Pres & Director (Age 57)
Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
Dr. Norbert W. Bischofberger, Exec. VP of R&D and Chief Scientific Officer (Age 62)
Mr. Gregg H. Alton, Exec. VP of Corp. & Medical Affairs and Interim Head of International Commercial Operations (Age 52)
Mr. Kevin B. Young, Advisory (Age 60)

Has Gilead Sciences been receiving favorable news coverage?

Press coverage about GILD stock has been trending somewhat positive this week, according to Accern. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.18 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.33 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.07%), Northern Trust Corp (1.27%), Franklin Resources Inc. (1.03%), Amundi Pioneer Asset Management Inc. (0.65%), Boston Partners (0.62%) and OppenheimerFunds Inc. (0.54%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., CI Investments Inc., Swiss National Bank, Amundi Pioneer Asset Management Inc., Envestnet Asset Management Inc., Sentry Investments Corp., Franklin Resources Inc. and Legal & General Group Plc. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Farallon Capital Management LLC, State Treasurer State of Michigan, BlackRock Inc., PointState Capital LP, Diamond Hill Capital Management Inc., Millennium Management LLC and Mackay Shields LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $67.38.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $87.61 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		1,698 (Vote Outperform)
Underperform Votes:		649 (Vote Underperform)
Total Votes:		2,347

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

23 Wall Street analysts have issued ratings and price targets for Gilead Sciences in the last 12 months. Their average twelve-month price target is $88.1458, suggesting that the stock has a possible upside of 30.82%. The high price target for GILD is $105.00 and the low price target for GILD is $72.00. There are currently 9 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.64	2.61	2.57
Ratings Breakdown:	0 Sell Rating(s) 9 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 11 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 12 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$88.1458	$88.7033	$86.8596	$84.5987
Price Target Upside:	30.82% upside	17.53% upside	7.35% upside	14.68% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/2/2018	Needham & Company LLC	Reiterated Rating	Hold		High
5/2/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$85.00 ➝ $81.00	Low
5/2/2018	Barclays	Lower Price Target	Overweight ➝ Buy	$95.00 ➝ $90.00	High
5/2/2018	Leerink Swann	Set Price Target	Market Perform	$80.00 ➝ $72.00	High
4/17/2018	Credit Suisse Group	Set Price Target	Hold	$80.00	Low
2/23/2018	Royal Bank of Canada	Reiterated Rating	Buy	$94.00	Low
2/12/2018	Mizuho	Reiterated Rating	Buy ➝ Buy	$83.00 ➝ $95.00	Low
2/8/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Market Perform	$86.00 ➝ $88.00	High
2/8/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$103.00 ➝ $105.00	High
2/7/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$82.00 ➝ $87.00	Medium
2/6/2018	Maxim Group	Set Price Target	Buy	$94.00	High
1/26/2018	Jefferies Group	Upgrade	Hold ➝ Buy	$81.19 ➝ $93.00	High
1/16/2018	Wells Fargo & Co	Upgrade	Market Perform ➝ Outperform	$79.02 ➝ $96.00	Low
12/21/2017	Oppenheimer	Reiterated Rating	Hold		Medium
11/13/2017	Argus	Downgrade	Buy ➝ Hold	$73.25 ➝ $73.77	N/A
10/25/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$85.00	N/A
10/19/2017	William Blair	Reiterated Rating	Buy		N/A
10/19/2017	Berenberg Bank	Set Price Target	Buy	$96.00	N/A
10/5/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		N/A
8/31/2017	Cowen	Reiterated Rating	Outperform	$90.00	Medium
8/31/2017	Deutsche Bank	Reiterated Rating	Buy	$81.00	Medium
8/29/2017	Robert W. Baird	Reiterated Rating	Outperform	$87.00	Low
7/26/2017	Redburn Partners	Initiated Coverage	Buy		Medium
5/3/2017	Gabelli	Reiterated Rating	Buy	$85.00	Medium
5/3/2017	Stifel Nicolaus	Reiterated Rating	Buy	$87.00	Medium
4/21/2017	Piper Jaffray Companies	Reiterated Rating	Buy		Low
3/13/2017	Goldman Sachs Group	Reiterated Rating	Neutral	$70.00 ➝ $68.00	Low
3/9/2017	UBS	Reiterated Rating	Neutral ➝ Neutral	$118.00 ➝ $72.00	N/A
10/15/2016	Evercore ISI	Set Price Target	Buy	$90.00	N/A
7/27/2016	S&P Equity Research	Reiterated Rating	Strong-Buy		N/A

(Data available from 5/28/2016 forward)

Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $5.99

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$1.55	$1.79	$1.67
Q2 2018	3	$1.35	$1.46	$1.40
Q3 2018	3	$1.38	$1.66	$1.48
Q4 2018	3	$1.31	$1.66	$1.43

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/24/2018		$1.55					N/A
5/1/2018	Q1 2018	$1.67	$1.48	$5.4042 billion	$5.0880 billion	View	Listen
2/6/2018	Q4 2017	$1.67	$1.78	$5.7118 billion	$5.9490 billion	View	Listen
10/26/2017	Q3 2017	$2.13	$2.27	$6.3970 billion	$6.5120 billion	View	N/A
7/26/2017	Q2 2017	$2.11	$2.56	$6.3503 billion	$7.1410 billion	View	N/A
5/2/2017	Q1 2017	$2.18	$2.20	$6.6604 billion	$6.5050 billion	View	Listen
2/7/2017	Q416	$2.61	$2.70	$7.16 billion	$7.30 billion	View	Listen
11/1/2016	Q316	$2.87	$2.75	$7.47 billion	$7.40 billion	View	Listen
7/25/2016	Q216	$3.02	$3.08	$7.80 billion	$7.78 billion	View	Listen
4/28/2016	Q116	$3.13	$3.03	$8.08 billion	$7.80 billion	View	Listen
2/2/2016	Q415	$3.00	$3.32	$8.11 billion	$8.51 billion	View	Listen
10/27/2015	Q315	$2.87	$3.22	$7.84 billion	$8.30 billion	View	Listen
7/28/2015	Q215	$2.83	$3.15	$7.60 billion	$8.2240 billion	View	Listen
4/30/2015	Q115	$2.78	$2.94	$6.81 billion	$7.59 billion	View	Listen
2/3/2015	Q414	$2.27	$2.43	$6.68 million	$7.3140 billion	View	Listen
10/28/2014	Q314	$1.92	$1.84	$5.99 billion	$6.04 billion	View	Listen
7/23/2014	Q214	$1.61	$2.36	$5.68 billion	$6.53 billion	View	Listen
4/22/2014	Q114	$0.75	$1.48	$3.80 billion	$4.9990 billion	View	Listen
2/4/2014	Q413	$0.50	$0.55	$2.85 billion	$3.04 billion	View	Listen
10/29/2013	Q313	$0.48	$0.52	$2.72 billion	$2.7828 billion	View	Listen
7/25/2013	Q2 2013	$0.50	$0.50	$2.66 billion	$2.77 billion	View	Listen
5/2/2013	Q1 2013	$0.50	$0.48	$2.5687 billion	$2.5316 billion	View	Listen
2/4/2013	Q4 2012	$0.48	$0.50	$2.43 billion	$2.5880 billion	View	Listen
10/23/2012		$0.94	$1.00			View	N/A
7/26/2012		$0.95	$0.99			View	N/A
4/26/2012		$0.94	$0.91			View	N/A
2/2/2012		$1.04	$0.97			View	N/A
10/27/2011		$1.01	$1.02			View	N/A
7/26/2011	Q2 2011	$0.48	$0.47			View	N/A
4/20/2011		$0.97	$0.87			View	N/A
1/25/2011		$0.95	$0.95			View	N/A
10/19/2010	Q3 2010	$0.42	$0.43			View	N/A
7/20/2010	Q2 2010	$0.41	$0.40			View	N/A
4/20/2010	Q1 2010	$0.46	$0.47			View	N/A
1/26/2010	Q4 2009	$0.41	$0.45			View	N/A
10/20/2009	Q3 2009	$0.35	$0.37			View	N/A
7/21/2009	Q2 2009	$0.31	$0.33			View	N/A
4/21/2009	Q1 2009	$0.30	$0.32			View	N/A
1/27/2009	Q4 2008	$0.28	$0.30			View	N/A
10/16/2008	Q3 2008	$0.25	$0.26			View	N/A
7/17/2008	Q2 2008	$0.25	$0.23			View	N/A
4/16/2008	Q1 2008	$0.24	$0.26			View	N/A
1/23/2008	Q4 2007	$0.21	$0.21			View	N/A

(Earnings results data provided by Zacks Investment Research)

Gilead Sciences (NASDAQ:GILD) Dividend Information

Gilead Sciences pays an annual dividend of $2.28 per share, with a dividend yield of 3.38%. GILD's next quarterly dividend payment will be made on Thursday, June 28. Gilead Sciences pays out 26.64% of its earnings out as a dividend.

Next Dividend:	6/28/2018
Annual Dividend:	$2.28
Dividend Yield:	3.38%
Payout Ratio(s):	26.64% (Trailing 12 Months of Earnings) 39.65% (Based on This Year's Estimates) 36.66% (Based on Next Year's Estimates) 23.69% (Based on Cash Flow)

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/1/2018	quarterly	$0.57	3.14%	6/14/2018	6/15/2018	6/28/2018
2/6/2018	quarterly	$0.57	3.02%	3/15/2018	3/16/2018	3/29/2018
10/26/2017	quarterly	$0.52	2.7%	12/14/2017	12/15/2017	12/28/2017
7/26/2017	quarterly	$0.52	2.78%	9/14/2017	9/15/2017	9/28/2017
5/2/2017	quarterly	$0.52	3.09%	6/14/2017	6/16/2017	6/29/2017
2/7/2017	quarterly	$0.52	3.11%	3/14/2017	3/16/2017	3/30/2017
11/1/2016	quarterly	$0.47	2.59%	12/13/2016	12/15/2016	12/29/2016
7/25/2016	quarterly	$0.47	2.32%	9/14/2016	9/16/2016	9/29/2016
4/28/2016	quarterly	$0.47	2.13%	6/14/2016	6/16/2016	6/29/2016
2/2/2016	quarterly	$0.43	1.99%	3/14/2016	3/16/2016	3/30/2016
10/27/2015	quarterly	$0.43	1.59%	12/14/2015	12/16/2015	12/30/2015
7/28/2015	quarterly	$0.43	1.49%	9/14/2015	9/16/2015	9/29/2015
4/30/2015	quarterly	$0.43		6/12/2015	6/16/2015	6/29/2015

(Data available from 1/1/2013 forward)

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 77.72%

Insider Trading History for Gilead Sciences (NASDAQ:GILD)

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2018	John Francis Cogan	Director	Sell	5,836	$65.09	$379,865.24	58,455
5/1/2018	John C Martin	Director	Sell	50,000	$72.19	$3,609,500.00	3,067,762
4/27/2018	John Francis Cogan	Director	Sell	5,833	$73.91	$431,117.03	58,452
4/20/2018	John Francis Cogan	Director	Sell	5,833	$73.74	$430,125.42	58,452
4/13/2018	John Francis Cogan	Director	Sell	5,833	$75.56	$440,741.48	58,452
4/6/2018	John Francis Cogan	Director	Sell	5,833	$74.47	$434,383.51	58,452
4/2/2018	John C Martin	Director	Sell	50,000	$73.14	$3,657,000.00	3,067,762
3/23/2018	John Francis Cogan	Director	Sell	5,833	$75.02	$437,591.66	58,452
3/16/2018	John Francis Cogan	Director	Sell	5,833	$80.09	$467,164.97	58,452
3/12/2018	John Francis Cogan	Director	Sell	5,833	$80.93	$472,064.69
3/1/2018	Gregg H Alton	EVP	Sell	25,000	$78.69	$1,967,250.00	69,426
3/1/2018	John C Martin	Chairman	Sell	50,000	$78.65	$3,932,500.00	3,067,762
2/28/2018	Robin L Washington	CFO	Sell	5,000	$80.31	$401,550.00	23,749
2/20/2018	Gregg H Alton	EVP	Sell	14,435	$81.54	$1,177,029.90
2/9/2018	Gayle E Wilson	Director	Sell	60,000	$77.92	$4,675,200.00	182,258
2/1/2018	Gregg H Alton	EVP	Sell	25,000	$83.51	$2,087,750.00	62,738
2/1/2018	John C Martin	Chairman	Sell	50,000	$83.56	$4,178,000.00	3,046,766
1/16/2018	James R Meyers	EVP	Sell	100,000	$80.24	$8,024,000.00	102,715
1/11/2018	Gregg H Alton	EVP	Sell	30,000	$79.00	$2,370,000.00	57,114
1/2/2018	Gregg H Alton	EVP	Sell	15,000	$73.87	$1,108,050.00	64,613
1/2/2018	John C Martin	Insider	Sell	50,000	$73.62	$3,681,000.00	3,046,766
12/1/2017	Gregg H Alton	EVP	Sell	15,000	$74.64	$1,119,600.00	70,988
12/1/2017	John C Martin	Insider	Sell	73,333	$74.98	$5,498,508.34	3,070,099
11/13/2017	John F Milligan	Insider	Sell	220,000	$72.88	$16,033,600.00
11/1/2017	Gregg H Alton	EVP	Sell	15,000	$74.82	$1,122,300.00	77,363
11/1/2017	John C Martin	Insider	Sell	73,333	$75.13	$5,509,508.29	3,070,099
10/2/2017	Gregg H Alton	EVP	Sell	25,000	$82.65	$2,066,250.00
10/2/2017	John C Martin	Insider	Sell	73,333	$82.56	$6,054,372.48
9/7/2017	Robin L Washington	CFO	Sell	51,820	$85.00	$4,404,700.00	43,352
9/1/2017	Gregg H Alton	EVP	Sell	25,000	$83.05	$2,076,250.00	101,488
9/1/2017	John C Martin	Insider	Sell	73,333	$83.11	$6,094,705.63	2,996,766
8/31/2017	James R Meyers	EVP	Sell	60,000	$83.19	$4,991,400.00	62,715
8/30/2017	Gregg H Alton	EVP	Sell	50,000	$79.00	$3,950,000.00	113,237
8/1/2017	Gregg H Alton	EVP	Sell	15,000	$75.88	$1,138,200.00	106,113
8/1/2017	John C Martin	Insider	Sell	73,333	$75.86	$5,563,041.38	3,199,969
7/21/2017	Gregg H Alton	EVP	Sell	40,000	$74.00	$2,960,000.00	137,488
7/3/2017	Gregg H Alton	EVP	Sell	5,000	$71.06	$355,300.00	102,988
7/3/2017	John C Martin	Insider	Sell	73,333	$71.00	$5,206,643.00	3,199,969
5/9/2017	John Francis Cogan	Director	Sell	9,943	$67.25	$668,666.75	47,562
4/3/2017	John C Martin	Insider	Sell	73,333	$67.18	$4,926,510.94	3,199,969
3/30/2017	Gregg H Alton	EVP	Sell	5,000	$67.48	$337,400.00	117,988
1/3/2017	John C Martin	Insider	Sell	73,337	$73.59	$5,396,869.83	3,204,433
11/18/2016	John W Madigan	Director	Sell	105,000	$74.86	$7,860,300.00	121,761
10/3/2016	John C Martin	Insider	Sell	100,000	$77.63	$7,763,000.00	3,231,096
9/22/2016	Gregg H Alton	EVP	Sell	5,000	$81.84	$409,200.00	132,964
9/6/2016	John F Milligan	Insider	Sell	70,000	$77.74	$5,441,800.00	1,128,963
9/1/2016	John C Martin	Insider	Sell	100,000	$77.48	$7,748,000.00	3,287,810
8/24/2016	Kevin E Lofton	Director	Sell	3,500	$81.97	$286,895.00
8/1/2016	John C Martin	Insider	Sell	100,000	$80.50	$8,050,000.00	4,119,727
8/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$79.81	$159,620.00	64,122
7/5/2016	John F Milligan	CEO	Sell	112,000	$84.33	$9,444,960.00	1,170,963
7/1/2016	John C Martin	Chairman	Sell	100,000	$84.73	$8,473,000.00	4,119,727
7/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$83.12	$166,240.00	63,122
6/6/2016	John F Milligan	CEO	Sell	112,000	$86.94	$9,737,280.00	1,170,963
6/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$87.02	$174,040.00	63,122
5/2/2016	John C Martin	Chairman	Sell	100,000	$87.82	$8,782,000.00	4,119,727
5/2/2016	John F Milligan	CEO	Sell	112,000	$87.71	$9,823,520.00	1,170,963
5/2/2016	Paul Rutherford Carter	EVP	Sell	2,000	$88.72	$177,440.00	62,939
4/19/2016	Gregg H Alton	EVP	Sell	40,000	$100.01	$4,000,400.00	177,964
4/4/2016	John F Milligan	CEO	Sell	112,000	$94.59	$10,594,080.00	1,170,963
4/1/2016	John C Martin	Chairman	Sell	100,000	$93.24	$9,324,000.00	4,119,727
4/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$91.34	$182,680.00	63,122
3/14/2016	Gregg H Alton	EVP	Sell	5,000	$90.00	$450,000.00	147,090
2/26/2016	Gayle E Wilson	Director	Sell	6,650	$90.61	$602,556.50	110,523
2/1/2016	John C. Martin	CEO	Sell	100,000	$83.42	$8,342,000.00	3,948,066
2/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$82.32	$164,640.00	48,783
1/4/2016	John C. Martin	CEO	Sell	100,000	$97.68	$9,768,000.00	3,948,066
1/4/2016	Paul Rutherford Carter	EVP	Sell	2,000	$99.20	$198,400.00	48,783
12/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$102.41	$7,168,700.00	127,936
12/7/2015	John F. Milligan	COO	Sell	100,000	$103.18	$10,318,000.00	1,029,108
11/24/2015	John Francis Cogan	Director	Sell	15,000	$105.95	$1,589,250.00	44,309
11/2/2015	Gregg H. Alton	EVP	Sell	12,000	$109.38	$1,312,560.00	131,422
11/2/2015	John C. Martin	CEO	Sell	150,000	$109.42	$16,413,000.00	3,948,066
11/2/2015	Robin L Washington	CFO	Sell	6,250	$109.46	$684,125.00
10/27/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
10/26/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00	133,422
10/26/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
10/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$100.05	$7,003,500.00	165,168
10/7/2015	John F. Milligan	COO	Sell	100,000	$99.22	$9,922,000.00	1,029,108
10/5/2015	Gregg H. Alton	EVP	Sell	5,000	$100.00	$500,000.00	133,422
10/1/2015	John C. Martin	CEO	Sell	150,000	$97.48	$14,622,000.00	3,948,066
10/1/2015	Paul Rutherford Carter	EVP	Sell	2,000	$98.59	$197,180.00	48,783
9/15/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00	135,422
9/15/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
9/8/2015	John F. Milligan	COO	Sell	100,000	$103.39	$10,339,000.00	1,029,108
9/2/2015	Robin L Washington	CFO	Sell	6,250	$102.20	$638,750.00
9/1/2015	John C. Martin	CEO	Sell	150,000	$102.73	$15,409,500.00	3,948,066
8/28/2015	Gayle E. Wilson	Director	Sell	21,000	$106.96	$2,246,160.00	101,769
8/25/2015	John C. Martin	CEO	Sell	133,213	$105.17	$14,010,011.21	3,948,066
8/17/2015	Norbert W Bischofberger	EVP	Sell	70,000	$116.16	$8,131,200.00
7/7/2015	John F Milligan	COO	Sell	100,000	$114.44	$11,444,000.00
6/26/2015	John Francis Cogan	Director	Sell	27,000	$120.13	$3,243,510.00
6/18/2015	Paul Rutherford Carter	EVP	Sell	10,000	$120.00	$1,200,000.00
6/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$117.67	$8,236,900.00
6/8/2015	John F Milligan	COO	Sell	100,000	$114.05	$11,405,000.00
6/1/2015	Gregg H Alton	EVP	Sell	17,000	$113.64	$1,931,880.00
6/1/2015	John C Martin	CEO	Sell	150,000	$113.95	$17,092,500.00
4/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$103.84	$7,268,800.00
4/8/2015	Paul Rutherford Carter	EVP	Sell	1,000	$100.00	$100,000.00
4/1/2015	Gregg H Alton	EVP	Sell	7,000	$96.53	$675,710.00
4/1/2015	John C Martin	CEO	Sell	150,000	$96.74	$14,511,000.00
3/2/2015	John C Martin	CEO	Sell	150,000	$103.51	$15,526,500.00
3/2/2015	Paul Rutherford Carter	EVP	Sell	2,000	$104.18	$208,360.00
3/2/2015	Richard James Whitley	Director	Sell	5,000	$103.43	$517,150.00
2/6/2015	Olsen Per Wold	Director	Buy	10,000	$99.92	$999,200.00
2/2/2015	Gregg H Alton	EVP	Sell	12,000	$105.73	$1,268,760.00
2/2/2015	John C Martin	CEO	Sell	150,000	$105.43	$15,814,500.00
2/2/2015	Robin L Washington	CFO	Sell	33,192	$105.38	$3,497,772.96
1/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$98.47	$6,892,900.00
1/8/2015	Gregg H Alton	EVP	Sell	5,000	$100.89	$504,450.00
1/5/2015	John C Martin	CEO	Sell	150,000	$95.12	$14,268,000.00
1/2/2015	Gregg H Alton	EVP	Sell	7,000	$95.17	$666,190.00
1/2/2015	Richard James Whitley	Director	Sell	5,000	$95.22	$476,100.00
12/22/2014	John Francis Cogan	Director	Sell	26,000	$95.03	$2,470,780.00
12/8/2014	John F Milligan	COO	Sell	146,823	$106.26	$15,601,411.98
12/1/2014	John C Martin	CEO	Sell	140,633	$100.72	$14,164,555.76
12/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$100.02	$200,040.00
11/3/2014	John C Martin	CEO	Sell	140,625	$110.40	$15,525,000.00
11/3/2014	Richard James Whitley	Director	Sell	5,000	$112.02	$560,100.00
11/3/2014	Robin L Washington	CFO	Sell	33,192	$110.26	$3,659,749.92
10/24/2014	Paul Rutherford Carter	EVP	Sell	2,000	$110.00	$220,000.00
10/7/2014	John F Milligan	COO	Sell	146,895	$104.60	$15,365,217.00
10/1/2014	John C Martin	CEO	Sell	140,625	$105.91	$14,893,593.75
10/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$106.39	$212,780.00
10/1/2014	Richard James Whitley	Director	Sell	5,000	$106.99	$534,950.00
9/26/2014	Paul Rutherford Carter	EVP	Sell	2,000	$107.47	$214,940.00
9/22/2014	John Francis Cogan	Director	Sell	5,000	$106.60	$533,000.00
9/8/2014	John F Milligan	COO	Sell	146,895	$105.99	$15,569,401.05
9/2/2014	Gregg H Alton	EVP	Sell	33,000	$108.58	$3,583,140.00
9/2/2014	John C Martin	CEO	Sell	140,625	$108.64	$15,277,500.00
8/26/2014	Paul Rutherford Carter	EVP	Sell	10,000	$106.16	$1,061,600.00
8/25/2014	Robin L Washington	CFO	Sell	4,304	$105.87	$455,664.48
8/21/2014	John Francis Cogan	Director	Sell	5,000	$101.09	$505,450.00
8/14/2014	Robin L Washington	CFO	Sell	33,556	$95.56	$3,206,611.36
8/1/2014	Gregg H Alton	EVP	Sell	33,000	$91.62	$3,023,460.00
8/1/2014	John C Martin	CEO	Sell	140,625	$91.53	$12,871,406.25
8/1/2014	Richard James Whitley	Director	Sell	5,000	$91.00	$455,000.00
8/1/2014	Robin L Washington	CFO	Sell	30,600	$91.48	$2,799,288.00
7/28/2014	Nicholas G Moore	Director	Sell	45,000	$90.56	$4,075,200.00
7/21/2014	John Francis Cogan	Director	Sell	5,000	$89.67	$448,350.00
7/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$86.45	$1,446,135.60
7/1/2014	Gregg H Alton	EVP	Sell	33,000	$84.12	$2,775,960.00
7/1/2014	John C Martin	CEO	Sell	140,625	$84.84	$11,930,625.00
7/1/2014	Richard James Whitley	Director	Sell	5,000	$83.65	$418,250.00
6/30/2014	Robin L Washington	CFO	Sell	10,400	$83.98	$873,392.00
6/23/2014	John Francis Cogan	Director	Sell	5,000	$81.82	$409,100.00
6/16/2014	Norbert W Bischofberger	EVP	Sell	90,000	$80.90	$7,281,000.00
6/9/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.43	$1,328,705.04
6/4/2014	Robin L Washington	CFO	Sell	6,426	$82.52	$530,273.52
6/2/2014	Gregg H Alton	EVP	Sell	33,000	$81.35	$2,684,550.00
6/2/2014	Richard James Whitley	Director	Sell	5,000	$80.95	$404,750.00
5/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$80.65	$7,258,500.00	119,302
5/6/2014	Robin Washington	CFO	Sell	3,000	$79.91	$239,730.00	49,832
5/1/2014	Gregg Alton	EVP	Sell	13,000	$79.08	$1,028,040.00	130,694
5/1/2014	John Martin	CEO	Sell	140,625	$79.02	$11,112,187.50	4,429,387
5/1/2014	Richard James Whitley	Director	Sell	5,000	$78.63	$393,150.00	12,778
5/1/2014	Robin Washington	CFO	Sell	27,600	$79.16	$2,184,816.00	49,832
4/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$67.03	$6,032,700.00	119,302
4/8/2014	John Francis Cogan	Director	Sell	5,000	$70.55	$352,750.00	39,542
4/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$70.53	$1,179,825.84	28,562
4/1/2014	Gregg Alton	EVP	Sell	13,000	$73.20	$951,600.00	132,694
4/1/2014	John Martin	CEO	Sell	140,625	$73.26	$10,302,187.50	4,429,387
3/14/2014	John Francis Cogan	Director	Sell	14,000	$76.44	$1,070,160.00	39,542
3/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$75.89	$6,830,100.00	119,302
3/10/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.32	$1,326,864.96	28,562
3/3/2014	Gregg Alton	EVP	Sell	33,000	$81.84	$2,700,720.00	84,484
3/3/2014	John Martin	CEO	Sell	140,625	$81.74	$11,494,687.50	4,257,235
2/26/2014	Nicholas Moore	Director	Sell	20,000	$84.05	$1,681,000.00
2/19/2014	Nicholas Moore	Director	Sell	19,068	$83.12	$1,584,932.16
1/23/2014	Kevin Young	EVP	Sell	100,000	$81.44	$8,144,000.00	216,418
1/21/2014	Gregg Alton	EVP	Sell	120,000	$80.00	$9,600,000.00	32,938
1/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$74.23	$6,680,700.00
10/23/2013	Kevin Young	EVP	Sell	75,000	$68.56	$5,142,000.00
10/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$62.54	$5,628,600.00	2,159,643
9/23/2013	Kevin Young	EVP	Sell	100,000	$62.88	$6,288,000.00	161,840
9/16/2013	Norbert Bischofberger	EVP	Sell	90,000	$63.11	$5,679,900.00	2,159,643
9/3/2013	Gregg Alton	EVP	Sell	30,000	$60.99	$1,829,700.00	46,938
9/3/2013	John Martin	CEO	Sell	282,242	$60.97	$17,208,294.74	4,057,121
8/30/2013	Nicholas Moore	Director	Sell	151,720	$60.42	$9,166,922.40
8/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$58.77	$5,289,300.00	2,159,643
8/1/2013	Gregg H Alton	EVP	Sell	30,000	$61.49	$1,844,700.00
8/1/2013	John C Martin	CEO	Sell	282,242	$61.61	$17,388,929.62
7/30/2013	John W Madigan	Director	Sell	249,000	$61.97	$15,430,530.00
7/15/2013	Norbert W Bischofberger	EVP	Sell	90,000	$57.33	$5,159,700.00
7/2/2013	John Francis Cogan	Director	Sell	17,000	$51.66	$878,220.00
7/1/2013	Gregg H Alton	EVP	Sell	30,000	$52.09	$1,562,700.00
7/1/2013	John C Martin	CEO	Sell	282,242	$52.00	$14,676,584.00
7/1/2013	Robin L Washington	CFO	Sell	45,600	$52.01	$2,371,656.00
6/7/2013	John Francis Cogan	Director	Sell	110,000	$52.15	$5,736,500.00
6/3/2013	Gregg H Alton	EVP	Sell	30,000	$52.77	$1,583,100.00
6/3/2013	John C Martin	CEO	Sell	282,242	$52.84	$14,913,667.28
2/28/2013	Olsen Per Wold	Director	Buy	10,000	$43.05	$430,500.00
12/3/2012	Gregg H Alton	EVP	Sell	44,000	$75.10	$3,304,400.00
12/3/2012	John C Martin	CEO	Sell	291,000	$75.01	$21,827,910.00
11/12/2012	Robin L Washington	CFO	Sell	55,950	$73.11	$4,090,504.50
10/3/2012	John F Milligan	COO	Sell	140,000	$69.85	$9,779,000.00
10/2/2012	Robin L Washington	CFO	Sell	29,500	$68.62	$2,024,290.00
9/4/2012	Gregg H Alton	EVP	Sell	44,000	$57.50	$2,530,000.00

(Data available from 1/1/2013 forward)

Gilead Sciences (NASDAQ GILD) News Headlines

Source:

Date	Headline
	Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead www.msn.com - May 24 at 3:14 PM
	Will “Right to Try” Bill Boost Biotech ETFs? finance.yahoo.com - May 24 at 3:14 PM
	Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief ... www.businesswire.com - May 24 at 5:01 AM
	Gilead: Novartis's Kymriah Is Coming To America seekingalpha.com - May 24 at 5:01 AM
	Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 finance.yahoo.com - May 24 at 5:01 AM
	Kraig Labs' new DNA Synthesis breakthrough could unlock the Revenue Streams door www.marketwatch.com - May 23 at 3:01 PM
	He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter www.bizjournals.com - May 23 at 3:01 PM
	He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter finance.yahoo.com - May 23 at 3:01 PM
	How Are Tesaro’s Valuations and Cash Flows? finance.yahoo.com - May 22 at 3:06 PM
	Tesaro Stock: What’s the Upside Potential? finance.yahoo.com - May 22 at 3:06 PM
	Gilead: Where's The Next Catalyst? seekingalpha.com - May 18 at 3:07 PM
	EU warns of possible birth defect link to GSK's HIV drug finance.yahoo.com - May 18 at 3:07 PM
	Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript) seekingalpha.com - May 17 at 5:31 AM
	$5.15 Billion in Sales Expected for Gilead Sciences (GILD) This Quarter www.americanbankingnews.com - May 17 at 1:56 AM
	Gilead Sciences Stock: How Much Upside Do Analysts Expect? finance.yahoo.com - May 16 at 3:15 PM
	A Look at Gilead Sciences’ Competitive Scenario finance.yahoo.com - May 16 at 3:15 PM
	Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018 finance.yahoo.com - May 16 at 3:15 PM
	FDA OKs expanded use for Gilead's Truvada seekingalpha.com - May 16 at 5:00 AM
	Gilead Sciences Says FDA Approves Once-daily Oral Truvada www.nasdaq.com - May 16 at 5:00 AM
	Brokerages Expect Gilead Sciences (GILD) to Announce $1.52 EPS www.americanbankingnews.com - May 15 at 9:22 PM
	BRIEF-Gilead's Kite Announces New Facilities, Expands Collaboration With National Cancer Institute www.reuters.com - May 15 at 3:01 PM
	Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell ... www.businesswire.com - May 15 at 3:01 PM
	Kite Pharma continues buildout for cell therapy manufacture seekingalpha.com - May 15 at 3:01 PM
	Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 ... www.streetinsider.com - May 15 at 3:01 PM
	Gilead Sciences: Resist Sentiment, Stop Speculating And Invest seekingalpha.com - May 15 at 3:01 PM
	Why Trump’s drug-price pitch makes no sense finance.yahoo.com - May 14 at 3:09 PM
	Form 4 GILEAD SCIENCES INC For: May 09 Filed by: Whitley Richard James www.streetinsider.com - May 12 at 3:04 PM
	Form 3 GILEAD SCIENCES INC For: May 09 Filed by: MANWANI HARISH www.streetinsider.com - May 12 at 3:04 PM
	You should know the cost of a drug or procedure before it... finance.yahoo.com - May 12 at 7:09 AM
	Final Trade: IBB, GILD & more finance.yahoo.com - May 12 at 7:09 AM
	Gilead May Rebound By 12% Short Term finance.yahoo.com - May 10 at 3:09 PM
	Harish Manwani Joins Gilead Sciences’ Board of Directors finance.yahoo.com - May 10 at 5:01 AM
	Lipotoxicity And NASH: Gilead's Actions Speak Louder Than Words seekingalpha.com - May 9 at 3:12 PM
	What Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial Strength finance.yahoo.com - May 9 at 5:09 AM
	Gilead Sciences (GILD) Director Sells $379,865.24 in Stock www.americanbankingnews.com - May 8 at 4:15 PM
	Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16 www.businesswire.com - May 8 at 3:02 PM
	UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing finance.yahoo.com - May 8 at 5:15 AM
	Gilead Sciences (GILD) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - May 7 at 1:13 PM
	Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space? finance.yahoo.com - May 7 at 8:01 AM
	Wall Street Recommendations for Exelixis in May 2018 finance.yahoo.com - May 7 at 8:01 AM
	Gilead Sciences (GILD) Expected to Earn Q2 2018 Earnings of $1.40 Per Share www.americanbankingnews.com - May 7 at 2:11 AM
	Q2 2018 Earnings Estimate for Gilead Sciences Issued By Leerink Swann (GILD) www.americanbankingnews.com - May 7 at 2:11 AM
	William Blair Analysts Cut Earnings Estimates for Gilead Sciences (GILD) www.americanbankingnews.com - May 7 at 2:11 AM
	Gilead Sciences (GILD) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - May 6 at 11:38 AM
	Notable Friday Option Activity: GILD, EXEL, RIG www.nasdaq.com - May 5 at 5:07 AM
	BidaskClub Downgrades Gilead Sciences (GILD) to Strong Sell www.americanbankingnews.com - May 5 at 12:29 AM
	Is Gilead Sciences Stock Finally a Bargain? finance.yahoo.com - May 4 at 3:13 PM
	Top Stock Reports for BP, Gilead, Enterprise Products & Colgate finance.yahoo.com - May 4 at 3:13 PM
	Allergan Reports Growth in 1Q18 Revenues finance.yahoo.com - May 4 at 3:13 PM
	Gilead Sciences, Inc. Stock Will Recover… Eventually finance.yahoo.com - May 4 at 5:15 AM

Gilead Sciences (NASDAQ:GILD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement

Gilead Sciences (NASDAQ GILD) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff